View Filing Data

Print Document View Excel Document

DOCUMENT AND ENTITY INFORMATION - shares	6 Months Ended
DOCUMENT AND ENTITY INFORMATION - shares	Sep. 30, 2017	Nov. 03, 2017
Document And Entity Information [Abstract]
Entity Registrant Name	HAEMONETICS CORP
Entity Central Index Key	0000313143
Current Fiscal Year End Date	--03-31
Entity Filer Category	Large Accelerated Filer
Document Type	10-Q
Document Period End Date	Sep. 30, 2017
Document Fiscal Year Focus	2018
Document Fiscal Period Focus	Q2
Amendment Flag	false
Entity Common Stock, Shares Outstanding		52,818,234

CONSOLIDATED STATEMENTS OF INCOME AND COMPREHENSIVE INCOME - USD ($) shares in Thousands, $ in Thousands	3 Months Ended		6 Months Ended
	Sep. 30, 2017	Oct. 01, 2016	Sep. 30, 2017	Oct. 01, 2016
Income Statement [Abstract]
Net revenues	$ 225,377	$ 220,253	$ 436,328	$ 430,209
Cost of goods sold	120,815	116,005	240,101	234,905
Gross profit	104,562	104,248	196,227	195,304
Operating expenses:
Research and development	7,521	8,336	15,714	19,773
Selling, general and administrative	72,783	71,118	139,644	158,618
Total operating expenses	80,304	79,454	155,358	178,391
Operating income	24,258	24,794	40,869	16,913
Gain on divestiture	0	0	8,000	0
Interest and other expense, net	(1,397)	(1,962)	(2,756)	(4,139)
Income before provision for income taxes	22,861	22,832	46,113	12,774
Provision for income taxes	2,759	3,007	5,874	3,295
Net income	$ 20,102	$ 19,825	$ 40,239	$ 9,479
Net earnings per share - basic (in dollars per share)	$ 0.38	$ 0.39	$ 0.77	$ 0.19
Net earnings per share - diluted (in dollars per share)	$ 0.38	$ 0.38	$ 0.76	$ 0.18
Weighted average shares outstanding
Basic (in shares)	52,619	51,378	52,531	51,200
Diluted (in shares)	52,981	51,701	52,896	51,463
Comprehensive income	$ 21,937	$ 19,037	$ 45,703	$ 7,804

CONSOLIDATED BALANCE SHEETS - USD ($) $ in Thousands	Sep. 30, 2017	Apr. 01, 2017
Current assets:
Cash and cash equivalents	$ 203,622	$ 139,564
Accounts receivable, less allowance of $2,224 at September 30, 2017 and $2,184 at April 1, 2017	143,693	152,683
Inventories, net	168,592	176,929
Prepaid expenses and other current assets	37,482	40,853
Total current assets	553,389	510,029
Property, plant and equipment, net	320,221	323,862
Intangible assets, less accumulated amortization of $232,714 at September 30, 2017 and $215,772 at April 1, 2017	169,379	177,540
Goodwill	211,125	210,841
Deferred tax asset	4,478	3,988
Other long-term assets	12,571	12,449
Total assets	1,271,163	1,238,709
Current liabilities:
Notes payable and current maturities of long-term debt	108,589	61,022
Accounts payable	41,764	42,973
Accrued payroll and related costs	37,364	43,534
Other liabilities	67,282	63,650
Total current liabilities	254,999	211,179
Long-term debt, net of current maturities	178,015	253,625
Deferred tax liability	13,380	12,114
Other long-term liabilities	23,516	22,181
Total stockholders’ equity
Common stock, $0.01 par value; Authorized — 150,000,000 shares; Issued and outstanding — 52,694,556 shares at September 30, 2017 and 52,255,495 shares at April 1, 2017	527	523
Additional paid-in capital	497,980	482,044
Retained earnings	330,155	289,916
Accumulated other comprehensive loss	(27,409)	(32,873)
Total stockholders’ equity	801,253	739,610
Total liabilities and stockholders’ equity	$ 1,271,163	$ 1,238,709

CONSOLIDATED BALANCE SHEETS (Parentheticals) - USD ($) $ in Thousands	Sep. 30, 2017	Apr. 01, 2017
Statement of Financial Position [Abstract]
Accounts receivable, allowance	$ 2,224	$ 2,184
Intangible assets, amortization	$ 232,714	$ 215,772
Common stock, par value (in dollars per share)	$ 0.01	$ 0.01
Common stock, shares authorized (in shares)	150,000,000	150,000,000
Common stock, shares issued (in shares)	52,694,556	52,255,495
Common stock, shares outstanding (in shares)	52,694,556	52,255,495

CONSOLIDATED STATEMENTS OF CASH FLOWS - USD ($) $ in Thousands	6 Months Ended
	Sep. 30, 2017	Oct. 01, 2016
Cash Flows from Operating Activities:
Net income	$ 40,239	$ 9,479
Non-cash items:
Depreciation and amortization	43,986	45,253
Gain on divestiture	(8,000)	0
Stock-based compensation expense	4,199	4,235
Provision for losses on accounts receivable and inventory	688	6,902
Impairment of assets	0	2,505
Other non-cash operating activities	312	(1,241)
Change in operating assets and liabilities:
Change in accounts receivable	10,739	6,807
Change in inventories	7,284	(12,661)
Change in prepaid income taxes	776	(324)
Change in other assets and other liabilities	3,920	2,836
Change in accounts payable and accrued expenses	(6,815)	6,169
Net cash provided by operating activities	97,328	69,960
Cash Flows from Investing Activities:
Capital expenditures	(29,125)	(41,624)
Proceeds from divestiture	9,000	0
Proceeds from sale of property, plant and equipment	1,346	197
Net cash used in investing activities	(18,779)	(41,427)
Cash Flows from Financing Activities:
Repayment of term loan borrowings	(28,455)	(18,970)
Proceeds from employee stock purchase plan	1,622	1,979
Proceeds from exercise of stock options	10,120	13,532
Net increase (decrease) in short-term loans	417	(1,116)
Net cash used in financing activities	(16,296)	(4,575)
Effect of exchange rates on cash and cash equivalents	1,805	(211)
Net Change in Cash and Cash Equivalents	64,058	23,747
Cash and Cash Equivalents at Beginning of Period	139,564	115,123
Cash and Cash Equivalents at End of Period	203,622	138,870
Supplemental Disclosures of Cash Flow Information:
Interest paid	3,768	4,118
Income taxes paid	5,449	3,867
Transfers from inventory to fixed assets for placement of Haemonetics equipment	$ 3,965	$ 3,477

BASIS OF PRESENTATION	6 Months Ended
BASIS OF PRESENTATION	Sep. 30, 2017
Organization, Consolidation and Presentation of Financial Statements [Abstract]
BASIS OF PRESENTATION	BASIS OF PRESENTATION Basis of Presentation Our accompanying unaudited consolidated financial statements have been prepared in accordance with generally accepted accounting principles in the United States of America (“U.S. GAAP”) in the United States for interim financial information and with the instructions to Form 10-Q and Article 10 of Regulation S-X. Accordingly, they do not include all of the information and footnotes required by U.S. GAAP for complete financial statements. In the opinion of our management, all adjustments (consisting of normal recurring adjustments) considered necessary for a fair presentation have been included. All intercompany transactions have been eliminated. Operating results for the six months ended September 30, 2017 are not necessarily indicative of the results that may be expected for the full fiscal year ending March 31, 2018 or any other interim period. Operating results for the three months ended October 1, 2016 include an overstatement of net income, which was determined to be immaterial to all periods impacted. Absent this correction, our operating income and net income for the three and six months ended October 1, 2016 would have been $0.9 million and $1.2 million lower, respectively, than the amount included in the accompanying consolidated statements of income and comprehensive income. These unaudited consolidated financial statements should be read in conjunction with our audited consolidated financial statements and footnotes included in our annual report on Form 10-K for the fiscal year ended April 1, 2017. We consider events or transactions that occur after the balance sheet date but prior to the issuance of the financial statements to provide additional evidence relative to certain estimates or to identify matters that require additional disclosure. Refer to Note 3, Restructuring, for information pertaining to a restructuring initiative that was approved after the balance sheet date but prior to the issuance of the financial statements. There were no other subsequent events identified.

RECENT ACCOUNTING PRONOUNCEMENTS	6 Months Ended
RECENT ACCOUNTING PRONOUNCEMENTS	Sep. 30, 2017
New Accounting Pronouncements and Changes in Accounting Principles [Abstract]
RECENT ACCOUNTING PRONOUNCEMENTS	RECENT ACCOUNTING PRONOUNCEMENTS Standards Implemented In March 2016, the FASB issued ASU No. 2016-09, Compensation- Stock Compensation (Topic 718): Improvements to Employee Share-Based Payment Accounting. The purpose of the update is to simplify several areas of the accounting for share-based payment transactions. We adopted ASU No. 2016-09 on a prospective basis in our first quarter of fiscal 2018; therefore, prior periods have not been adjusted. The adoption of ASU No. 2016-09 did not have a material effect on our financial position or results of operations. ASU No. 2016-09 allows a company to elect to account for award forfeitures as they occur or to continue to estimate forfeitures. We have elected to continue to estimate potential forfeitures. In addition, ASU No. 2016-09 eliminates additional paid in capital pools and requires excess tax benefits and tax deficiencies to be recorded in the consolidated statement of operations when the awards vest or are settled. Amendments related to accounting for excess tax benefits resulted in an immaterial tax benefit for the three and six months ended September 30, 2017. In connection with the adoption of this new standard, we also recorded a cumulative-effect adjustment to accumulated deficit and deferred tax assets for certain off balance sheet federal and state net operating loss carry-forwards totaling $1.6 million as of April 1, 2017, with an equal offsetting adjustment to the valuation allowance.

- Definition

The entire disclosure of changes in accounting principles, including adoption of new accounting pronouncements, that describes the new methods, amount and effects on financial statement line items.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Glossary Change in Accounting Principle
-URI http://asc.fasb.org/extlink&oid=6507316

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Glossary Direct Effects of a Change in Accounting Principle
-URI http://asc.fasb.org/extlink&oid=66092750

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=64853466&loc=d3e22583-107794

Reference 4: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Glossary Indirect Effects of a Change in Accounting Principle
-URI http://asc.fasb.org/extlink&oid=6515603

Reference 5: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=64853466&loc=d3e22580-107794

Reference 6: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 270
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.10-01.(b)(6))
-URI http://asc.fasb.org/extlink&oid=27015980&loc=d3e46468-122699

Reference 7: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Glossary Accounting Change
-URI http://asc.fasb.org/extlink&oid=6503790

Reference 8: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=64853466&loc=d3e22499-107794

Reference 9: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Glossary Retrospective Application
-URI http://asc.fasb.org/extlink&oid=6523989

Reference 10: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 270
-SubTopic 10
-Section 45
-Paragraph 13
-URI http://asc.fasb.org/extlink&oid=68064558&loc=d3e765-108305

Reference 11: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 270
-SubTopic 10
-Section 45
-Paragraph 12
-URI http://asc.fasb.org/extlink&oid=68064558&loc=d3e725-108305

+ Details

RESTRUCTURING

6 Months Ended

Sep. 30, 2017

Restructuring and Related Activities [Abstract]

RESTRUCTURING

On an ongoing basis, we review the global economy, the healthcare industry, and the markets in which we compete to identify opportunities for efficiencies, enhance commercial capabilities, align our resources and offer our customers better solutions. In order to realize these opportunities, we undertake restructuring-type activities to transform our business.

On November 1, 2017, we launched a Complexity Reduction Initiative (the "2018 Program"), a company-wide restructuring program designed to improve operational performance and reduce cost, freeing up resources to invest in accelerated growth. This program includes a reduction of headcount and operating costs which will enable a more streamlined organizational structure. We expect to incur aggregate charges between $50 million and $60 million associated with these actions, of which we expect $35 million to $40 million will consist of severance and other employee costs and the remainder will consist of other exit costs, primarily related to third party services. These charges, substantially all of which will result in cash outlays, will be incurred as the specific actions required to execute on these initiatives are identified and approved and are expected to continue through fiscal 2020.

During fiscal 2017, we launched a restructuring program (the "2017 Program") designed to reposition our organization and improve our cost structure. During the three and six months ended September 30, 2017, we incurred $5.2 million and $7.7 million, respectively, of restructuring and turnaround costs under this program. During the three and six months ended October 1, 2016, we incurred $1.1 million and $18.8 million, respectively, of restructuring and turnaround charges under this program. As of September 30, 2017, the 2017 Program was substantially complete.

The following summarizes the restructuring activity for the six months ended September 30, 2017:



(In thousands)	Severance and Other Employee Costs			Other Costs			Total Restructuring
Balance at April 1, 2017	$	7,001		$	467		$	7,468
Costs incurred, net of reversals	446			761			1,207
Payments	(3,872		)	(470		)	(4,342		)
Balance at September 30, 2017	$	3,575		$	758		$	4,333

Substantially all of the restructuring costs for the six months ended September 30, 2017 have been included as a component of selling, general and administrative expenses in the accompanying consolidated statements of income. As of September 30, 2017, we had a restructuring liability of $4.3 million, of which approximately $3.9 million is payable within the next twelve months.

In addition to the restructuring costs included in the table above, during the three and six months ended September 30, 2017, we also incurred costs of $5.6 million and $7.1 million, respectively, that do not constitute restructuring under ASC 420, Exit and Disposal Cost Obligations, which we refer to as turnaround costs. These costs, substantially all of which have been included as a component of selling, general and administrative expenses in the accompanying consolidated statements of income, consist primarily of expenditures directly related to our restructuring initiative and include program management, implementation of the global strategic review initiatives and accelerated depreciation.

The tables below present restructuring and turnaround costs by reportable segment:



Restructuring costs	Three Months Ended					Six Months Ended
(in thousands)	September 30, 2017		October 1, 2016			September 30, 2017		October 1, 2016
Japan	$	2	$	(38	)	$	111	$	836
EMEA	15		(63		)	25		3,011
North America Plasma	—		(7		)	—		368
All Other	134		(246		)	1,071		11,817
Total	$	151	$	(354	)	$	1,207	$	16,032

Turnaround costs	Three Months Ended					Six Months Ended
(in thousands)	September 30, 2017		October 1, 2016			September 30, 2017		October 1, 2016
Japan	$	—	$	1		$	—	$	2
EMEA	20		55			26		81
North America Plasma	197		936			349		936
All Other	5,419		959			6,688		3,362
Total	$	5,636	$	1,951		$	7,063	$	4,381

Total restructuring and turnaround costs	$	5,787	$	1,597		$	8,270	$	20,413

DIVESTITURE	6 Months Ended
DIVESTITURE	Sep. 30, 2017
Discontinued Operations and Disposal Groups [Abstract]
DIVESTITURE	DIVESTITURE On April 27, 2017, we sold our SEBRA line of benchtop and hand sealers to Machine Solutions Inc. because it was no longer aligned with our long-term strategic objectives. In connection with this transaction, we received net proceeds of $9.0 million and recorded a pre-tax gain of $8.0 million. The proceeds were subject to a post-closing adjustment based on final asset values as determined during the 90 day transition period. During the second quarter of fiscal 2018, the 90 day transition period ended and there were no post-close adjustments necessary. The SEBRA portfolio included a suite of products which primarily include radio frequency sealers that are used to seal tubing as part of the collection of whole blood and blood components, particularly plasma.

- Definition

The entire disclosure related to a disposal group. Includes, but is not limited to, a discontinued operation, disposal classified as held-for-sale or disposed of by means other than sale or disposal of an individually significant component.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 205
-SubTopic 20
-Section 45
-Paragraph 11
-URI http://asc.fasb.org/extlink&oid=65878427&loc=SL51721533-107759

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 205
-SubTopic 20
-Section 50
-Paragraph 4B
-URI http://asc.fasb.org/extlink&oid=64827811&loc=SL51721665-107760

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 205
-SubTopic 20
-Section 50
-Paragraph 5C
-URI http://asc.fasb.org/extlink&oid=64827811&loc=SL51721675-107760

Reference 4: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 360
-SubTopic 10
-Section 50
-Paragraph 3A
-URI http://asc.fasb.org/extlink&oid=64862545&loc=SL51724579-110230

Reference 5: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 205
-SubTopic 20
-Section 50
-Paragraph 4A
-URI http://asc.fasb.org/extlink&oid=64827811&loc=SL51721663-107760

Reference 6: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 360
-SubTopic 10
-Section 50
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=64862545&loc=d3e2941-110230

Reference 7: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 205
-SubTopic 20
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=64827811&loc=d3e1361-107760

Reference 8: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 205
-SubTopic 20
-Section 50
-Paragraph 5B
-URI http://asc.fasb.org/extlink&oid=64827811&loc=SL51721673-107760

Reference 9: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 205
-SubTopic 20
-Section 50
-Paragraph 3A
-URI http://asc.fasb.org/extlink&oid=64827811&loc=SL51721659-107760

Reference 10: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 205
-SubTopic 20
-Section 50
-Paragraph 5A
-URI http://asc.fasb.org/extlink&oid=64827811&loc=SL51721671-107760

Reference 11: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 205
-SubTopic 20
-Section 50
-Paragraph 5D
-URI http://asc.fasb.org/extlink&oid=64827811&loc=SL51721677-107760

Reference 12: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 205
-SubTopic 20
-Section 50
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=64827811&loc=d3e1474-107760

Reference 13: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 205
-SubTopic 20
-Section 50
-Paragraph 7
-URI http://asc.fasb.org/extlink&oid=64827811&loc=SL51721683-107760

+ Details

INCOME TAXES	6 Months Ended
INCOME TAXES	Sep. 30, 2017
Income Tax Disclosure [Abstract]
INCOME TAXES	INCOME TAXES We conduct business globally and report our results of operations in a number of foreign jurisdictions in addition to the United States. Our reported tax rate is generally lower than the U.S. federal statutory rate as the income tax rates in the foreign jurisdictions in which we operate are generally lower than the U.S. statutory tax rate. Additionally, our reported tax rate is lower than the statutory tax rate as a result of the release of valuation allowance against tax attributes in certain jurisdictions which can be utilized to offset current year earnings. During the three months ended September 30, 2017 and October 1, 2016, we reported an income tax provision of $2.8 million and $3.0 million, respectively, representing effective tax rates of 12.1% and 13.2%, respectively. For the six months ended September 30, 2017 and October 1, 2016, we reported an income tax provision of $5.9 million and $3.3 million, respectively, representing effective tax rates of 12.7% and 25.8%, respectively. The change in our reported tax rate for both the three and six months ended September 30, 2017 was primarily the result of changes in the jurisdictional mix of earnings. Our effective tax rate for six months ended October 1, 2016 was also impacted by a non-recurring discrete tax expense of $1.4 million related to a workforce reduction during the first quarter of fiscal 2017 in a foreign subsidiary where we were required to maintain certain levels of headcount for a multi-year period, which resulted in the establishment of a tax reserve. The income tax provision for the six months ended September 30, 2017 was primarily attributable to applying our estimated annual effective tax rate to our year-to-date consolidated income before provision for income taxes. We are in a three year cumulative loss position in the U.S. and, accordingly, maintain a valuation allowance against our U.S. deferred tax assets. Additionally, we also maintain a valuation allowance against certain other deferred tax assets primarily in Switzerland, Puerto Rico, Luxembourg and France which we have concluded are not more-likely-than-not realizable.

EARNINGS PER SHARE ("EPS")

6 Months Ended

Sep. 30, 2017

Earnings Per Share [Abstract]

EARNINGS PER SHARE (EPS)

EARNINGS PER SHARE (“EPS”)

The following table provides a reconciliation of the numerators and denominators of the basic and diluted earnings per share computations.



	Three Months Ended				Six Months Ended
(In thousands, except per share amounts)	September 30, 2017		October 1, 2016		September 30, 2017		October 1, 2016
Basic EPS
Net income	$	20,102	$	19,825	$	40,239	$	9,479
Weighted average shares	52,619		51,378		52,531		51,200
Basic income per share	$	0.38	$	0.39	$	0.77	$	0.19
Diluted EPS
Net income	$	20,102	$	19,825	$	40,239	$	9,479
Basic weighted average shares	52,619		51,378		52,531		51,200
Net effect of common stock equivalents	362		323		365		263
Diluted weighted average shares	52,981		51,701		52,896		51,463
Diluted income per share	$	0.38	$	0.38	$	0.76	$	0.18

Basic earnings per share is calculated using our weighted-average outstanding common shares. Diluted earnings per share is calculated using our weighted-average outstanding common shares including the dilutive effect of stock awards as determined under the treasury stock method. For the three and six months ended September 30, 2017, weighted average shares outstanding, assuming dilution, excludes the impact of 0.9 million and 0.8 million anti-dilutive shares, respectively. For both the three and six months ended October 1, 2016, weighted average shares outstanding, assuming dilution, excludes the impact of 1.7 million anti-dilutive shares.

INVENTORIES

6 Months Ended

Sep. 30, 2017

Inventory Disclosure [Abstract]

INVENTORIES

Inventories are stated at the lower of cost or market and include the cost of material, labor and manufacturing overhead. Cost is determined using the first-in, first-out method.



(In thousands)	September 30, 2017		April 1, 2017
Raw materials	$	50,197	$	52,052
Work-in-process	12,234		10,400
Finished goods	106,161		114,477
Total inventories	$	168,592	$	176,929

CAPITALIZATION OF SOFTWARE DEVELOPMENT COSTS	6 Months Ended
CAPITALIZATION OF SOFTWARE DEVELOPMENT COSTS	Sep. 30, 2017
Research and Development [Abstract]
CAPITALIZATION OF SOFTWARE DEVELOPMENT COSTS	CAPITALIZATION OF SOFTWARE DEVELOPMENT COSTS For costs incurred related to the development of software to be sold, leased or otherwise marketed, we apply the provisions of ASC 985-20, Software - Costs of Software to be Sold, Leased or Marketed, which specifies that costs incurred internally in researching and developing a computer software product should be charged to expense until technological feasibility has been established for the product. Once technological feasibility is established, all software costs should be capitalized until the product is available for general release to customers. We capitalized $6.4 million in software development costs for ongoing initiatives during both the six months ended September 30, 2017 and October 1, 2016. At September 30, 2017 and April 1, 2017, we had a total of $69.1 million and $62.7 million of capitalized software costs, respectively, of which $19.1 million and $12.7 million are related to in-process software development initiatives, respectively. There were no capitalized costs placed into service during the six months ended September 30, 2017. During the six months ended October 1, 2016, $4.5 million of capitalized costs were placed into service. The costs capitalized for each project are included in intangible assets in the consolidated financial statements.

- Definition

The entire disclosure for research, development, and computer software activities, including contracts and arrangements to be performed for others and with federal government. Includes costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility and in-process research and development acquired in a business combination consummated during the period.

+ References + Details

PRODUCT WARRANTIES

6 Months Ended

Sep. 30, 2017

Product Warranties Disclosures [Abstract]

PRODUCT WARRANTIES

We generally provide warranty on parts and labor for one year after the sale and installation of each device. We also warrant our disposables products through their use or expiration. We estimate our potential warranty expense based on our historical warranty experience and periodically assess the adequacy of our warranty accrual, making adjustments as necessary.



	Six Months Ended
(In thousands)	September 30, 2017			October 1, 2016
Warranty accrual as of the beginning of the period	$	176		$	420
Warranty provision	796			390
Warranty spending	(537		)	(583		)
Warranty accrual as of the end of the period	$	435		$	227

DERIVATIVES AND FAIR VALUE MEASUREMENTS

6 Months Ended

Sep. 30, 2017

Derivative Instruments and Hedging Activities Disclosure [Abstract]

DERIVATIVES AND FAIR VALUE MEASUREMENTS

We manufacture, market and sell our products globally. During the three and six months ended September 30, 2017, 38.4% and 38.2% of our sales were generated outside the U.S., generally in foreign currencies. We also incur certain manufacturing, marketing and selling costs in international markets in local currency.

Accordingly, our earnings and cash flows are exposed to market risk from changes in foreign currency exchange rates relative to the U.S. Dollar, our reporting currency. We have a program in place that is designed to mitigate our exposure to changes in foreign currency exchange rates. That program includes the use of derivative financial instruments to minimize for a period of time, the impact on our financial results from changes in foreign exchange rates. We utilize foreign currency forward contracts to hedge the anticipated cash flows from transactions denominated in foreign currencies, primarily the Japanese Yen and the Euro, and to a lesser extent the Swiss Franc, Australian Dollar, Canadian Dollar and the Mexican Peso. This does not eliminate the impact of the volatility of foreign exchange rates. However, because we generally enter into forward contracts one year out, rates are fixed for a one-year period, thereby facilitating financial planning and resource allocation.

Designated Foreign Currency Hedge Contracts

All of our designated foreign currency hedge contracts as of September 30, 2017 and April 1, 2017 were cash flow hedges under ASC 815, Derivatives and Hedging ("ASC 815"). We record the effective portion of any change in the fair value of designated foreign currency hedge contracts in other comprehensive income until the related third-party transaction occurs. Once the related third-party transaction occurs, we reclassify the effective portion of any related gain or loss on the designated foreign currency hedge contracts to earnings. In the event the hedged forecasted transaction does not occur, or it becomes probable that it will not occur, we would reclassify the amount of any gain or loss on the related cash flow hedge to earnings at that time. We had designated foreign currency hedge contracts outstanding in the contract amount of $58.4 million as of September 30, 2017 and $68.4 million as of April 1, 2017. At September 30, 2017, losses of $1.4 million, net of tax, will be reclassified to earnings within the next twelve months. Substantially all currency cash flow hedges outstanding as of September 30, 2017 mature within twelve months.

Non-Designated Foreign Currency Contracts

We manage our exposure to changes in foreign currency on a consolidated basis to take advantage of offsetting transactions and balances. We use foreign currency forward contracts as a part of our strategy to manage exposure related to foreign currency denominated monetary assets and liabilities. These foreign currency forward contracts are entered into for periods consistent with currency transaction exposures, generally one month. They are not designated as cash flow or fair value hedges under ASC 815. These forward contracts are marked-to-market with changes in fair value recorded to earnings. We had non-designated foreign currency hedge contracts under ASC 815 outstanding in the contract amount of $37.6 million as of September 30, 2017 and $55.4 million as of April 1, 2017.

Interest Rate Swaps

On December 21, 2012, we entered into two interest rate swap agreements (the "Swaps") on a total notional amount of $250.0 million of debt. We designated the Swaps as cash flow hedges of variable interest rate risk associated with $250.0 million of indebtedness. For three and six months ended September 30, 2017 and October 1, 2016, we recorded nominal activity in accumulated other comprehensive loss to recognize the effective portion of the fair value of interest rate swaps that qualify as cash flow hedges. The Swaps matured on August 1, 2017.

Fair Value of Derivative Instruments

The following table presents the effect of our derivative instruments designated as cash flow hedges and those not designated as hedging instruments under ASC 815 in our consolidated statements of income and comprehensive income for the six months ended September 30, 2017:



(In thousands)	Amount of (Loss) Gain Recognized in Accumulated Other Comprehensive Loss			Amount of (Loss) Gain Reclassified from Accumulated Other Comprehensive Loss into Earnings			Location in Consolidated Statements of Income and Comprehensive Income	Amount of Gain (Loss) Excluded from Effectiveness Testing			Location in Consolidated Statements of Income and Comprehensive Income
Designated foreign currency hedge contracts, net of tax	$	(1,449	)	$	(121	)	Net revenues, COGS, and SG&A	$	601		Interest and other expense, net
Non-designated foreign currency hedge contracts	—			—				$	(881	)	Interest and other expense, net
Designated interest rate swaps, net of tax	$	(64	)				Interest and other expense, net

We did not have fair value hedges or net investment hedges outstanding as of September 30, 2017 or April 1, 2017. As of September 30, 2017, no deferred tax assets were recognized for designated foreign currency hedges.

ASC 815 requires all derivative instruments to be recognized at their fair values as either assets or liabilities on the balance sheet. We determine the fair value of our derivative instruments using the framework prescribed by ASC 820, Fair Value Measurements and Disclosures, by considering the estimated amount we would receive or pay to sell or transfer these instruments at the reporting date and by taking into account current interest rates, currency exchange rates, current interest rate curves, interest rate volatilities, the creditworthiness of the counterparty for assets, and our creditworthiness for liabilities. In certain instances, we may utilize financial models to measure fair value. Generally, we use inputs that include quoted prices for similar assets or liabilities in active markets; quoted prices for identical or similar assets or liabilities in markets that are not active; other observable inputs for the asset or liability; and inputs derived principally from, or corroborated by, observable market data by correlation or other means. As of September 30, 2017, we have classified our derivative assets and liabilities within Level 2 of the fair value hierarchy prescribed by ASC 815, as discussed below, because these observable inputs are available for substantially the full term of our derivative instruments.

The following tables present the fair value of our derivative instruments as they appear in our consolidated balance sheets as of September 30, 2017 and April 1, 2017:



(In thousands)	Location in Balance Sheet	As of September 30, 2017		As of April 1, 2017
Derivative Assets:
Designated foreign currency hedge contracts	Other current assets	$	1,093	$	1,645
Non-designated foreign currency hedge contracts	Other current assets	64		218
Designated interest rate swaps	Other current assets	—		64
		$	1,157	$	1,927
Derivative Liabilities:
Designated foreign currency hedge contracts	Other current liabilities	$	1,611	$	894
Non-designated foreign currency hedge contracts	Other current liabilities	141		72
		$	1,752	$	966

Other Fair Value Measurements

Fair value is defined as the exit price that would be received from the sale of an asset or paid to transfer a liability, using assumptions that market participants would use in pricing an asset or liability. The fair value guidance establishes the following three-level hierarchy used for measuring fair value:


•	Level 1 — Inputs to the valuation methodology are quoted market prices for identical assets or liabilities.


•	Level 2 — Inputs to the valuation methodology are other observable inputs, including quoted market prices for similar assets or liabilities and market-corroborated inputs.


•	Level 3 — Inputs to the valuation methodology are unobservable inputs based on management’s best estimate of inputs market participants would use in pricing the asset or liability at the measurement date, including assumptions about risk.

Our money market funds carried at fair value are classified within Level 1 of the fair value hierarchy because they are valued using quoted market prices.

Fair Value Measured on a Recurring Basis

Financial assets and financial liabilities measured at fair value on a recurring basis consist of the following as of September 30, 2017 and April 1, 2017.



	As of September 30, 2017
(In thousands)	Level 1		Level 2		Total
Assets
Money market funds	$	135,763	$	—	$	135,763
Designated foreign currency hedge contracts	—		1,093		1,093
Non-designated foreign currency hedge contracts	—		64		64
	$	135,763	$	1,157	$	136,920
Liabilities
Designated foreign currency hedge contracts	$	—	$	1,611	$	1,611
Non-designated foreign currency hedge contracts	—		141		141
	$	—	$	1,752	$	1,752

	As of April 1, 2017
	Level 1		Level 2		Total
Assets
Money market funds	$	80,676	$	—	$	80,676
Designated foreign currency hedge contracts	—		1,645		1,645
Non-designated foreign currency hedge contracts	—		218		218
Designated interest rate swaps	—		64		64
	$	80,676	$	1,927	$	82,603
Liabilities
Designated foreign currency hedge contracts	$	—	$	894	$	894
Non-designated foreign currency hedge contracts	—		72		72
	$	—	$	966	$	966

Other Fair Value Disclosures

The Term Loan (which is carried at amortized cost), accounts receivable and accounts payable approximate fair value.

COMMITMENTS AND CONTINGENCIES	6 Months Ended
COMMITMENTS AND CONTINGENCIES	Sep. 30, 2017
Commitments and Contingencies Disclosure [Abstract]
COMMITMENTS AND CONTINGENCIES	COMMITMENTS AND CONTINGENCIES The Company is a party to various other legal proceedings and claims arising out of the ordinary course of its business. We believe that except for those matters described below, there are no other proceedings or claims pending against us the ultimate resolution of which could have a material adverse effect on our financial condition or results of operations. At each reporting period, management evaluates whether or not a potential loss amount or a potential range of loss is probable and reasonably estimable under ASC 450, Contingencies, for all matters. Legal costs are expensed as incurred. Litigation and Related Matters Italian Employment Litigation Our Italian manufacturing subsidiary is party to several actions initiated by former employees of our facility in Ascoli-Piceno, Italy. We ceased operations at the facility in fiscal 2014 and sold the property in fiscal 2017. These include actions claiming (i) working conditions and minimum salaries should have been established by either a different classification under their national collective bargaining agreement or a different agreement altogether, (ii) certain solidarity agreements, which are arrangements between the Company, employees and the government to continue full pay and benefits for employees who would otherwise be terminated in times of low demand, are void, and (iii) rights to payment of the extra time used for changing into and out of the working clothes at the beginning and end of each shift. In addition, a union represented in the Ascoli plant filed an action claiming that the Company discriminated against it in favor of three other represented unions by (i) interfering with an employee referendum, (ii) interfering with an employee petition to recall union representatives from office, and (iii) excluding the union from certain meetings. Finally, we have been added as defendants on claims filed against Pall Corporation prior to our acquisition of the plant in August 2012. These claims relate to agreements to "freeze" benefit allowances for a certain period in exchange for Pall's commitments on hiring and plant investment. The total amount of damages claimed by the plaintiffs in these matters is approximately $4.8 million. During the second quarter of fiscal 2018, we proposed a settlement offer of $0.8 million, which resulted in charges of $0.4 million during the period. As of September 30, 2017, we have recorded a total liability of $0.8 million associated with these claims. In the future, we may receive adverse rulings from the courts which could change our judgment on these cases. SOLX Arbitration In July 2016, H2 Equity, LLC, formerly known as Hemerus Corporation, filed an arbitration claim for $17 million in milestone and royalty payments allegedly owed as part of our acquisition of the filter and storage solution business from Hemerus Medical, LLC ("Hemerus") in fiscal 2014. The acquired storage solution is referred to as SOLX. At the closing in April 2013, Haemonetics paid Hemerus a total of $24 million and agreed to a $3 million milestone payment due when the United States Food and Drug Administration ("FDA") approved a new indication for SOLX (the “24-Hour Approval”) using a filter acquired from Hemerus. We also agreed to make future royalty payments up to a cumulative maximum of $14 million based on the sale of products incorporating SOLX over a ten year period. Due to performance issues with the Hemerus filter, Haemonetics filed for, and received, the 24-Hour Approval using a Haemonetics filter. Accordingly, Haemonetics did not pay Hemerus the $3 million milestone payment because the 24-Hour Approval was obtained using a Haemonetics filter, not a Hemerus filter. In addition, we have not paid any royalties to date as we have not made any sales of products incorporating SOLX. H2 Equity claims, in part, that we owe it $3 million for the receipt of the 24-Hour Approval despite the use of a Haemonetics filter to obtain the approval and that we have failed to make commercially reasonable efforts to market and sell products incorporating SOLX. While we believe that we have meritorious defenses to these claims, as of September 30, 2017 we have recorded a liability of $0.4 million which is reflective of the current settlement discussions. Product Recall In June 2016, we issued a voluntary recall of certain whole blood collection kits sold to our Blood Center customers in the U.S. The recall resulted from some collection sets' filters failing to adequately remove leukocytes from collected blood. As a result of the recall, our blood center customers may have conducted further tests to confirm the blood was adequately leukoreduced, sold the blood labeled as non-leukoreduced at a lower price or discarded the blood collected using the defective sets. We recorded $7.1 million of charges during fiscal 2017, which consisted of $3.7 million of charges associated with customer returns and inventory reserves and $3.4 million of charges associated with customer claims. Although there have been no additional charges recorded in the current period, we may record incremental charges in future periods. The $3.4 million liability associated with customer claims are based on claims seeking reimbursement for $14.2 million in losses sustained as a result of the recall. We believe it is probable that we will incur expenses as a result of these claims and that our range of loss is $3.4 million to $14.2 million, however, we do not have sufficient information to develop a best estimate within this range. Accordingly, during fiscal 2017 we recorded a liability of $3.4 million, which represents the low end of the range. While the customers making these claims purchased substantially all the affected units, incremental charges may be recorded in future periods as additional customer returns and claims data becomes available. We have an enforceable insurance policy in place which we believe provides coverage for a portion of the claims received to date. Accordingly, as of September 30, 2017, we had an insurance receivable of $2.9 million. We will assess the potential for additional insurance recoveries as we receive more information about customer claims in future reporting periods. Other Matters In February 2017, we informed a customer of our intent to exit an existing contract. During the second quarter of fiscal 2018, the customer made a demand for $4.6 million, which consisted of $2.8 million in damages for non-performance under the contract and $1.8 million for the refund of two upfront payments that the customer had previously paid to us in connection with the development of a project. As of September 30, 2017, we concluded that it was probable that we would incur costs of $2.8 million in connection with this matter and accordingly have recorded have a liability to reflect this loss contingency. Additionally, we continue to maintain a deferred revenue liability of $1.8 million for the upfront payments, as we have not achieved all of the criteria necessary to recognize these payments as revenue.

SEGMENT AND ENTERPRISE-WIDE INFORMATION

6 Months Ended

Sep. 30, 2017

Segment Reporting [Abstract]

SEGMENT AND ENTERPRISE-WIDE INFORMATION

We determine our reportable segments by first identifying our operating segments, and then by assessing whether any components of these segments constitute a business for which discrete financial information is available and where segment management regularly reviews the operating results of that component. Our operating segments are based primarily on geography. North America Plasma is a separate operating segment with dedicated segment management due the size and scale of the Plasma business unit. We aggregate components within an operating segment that have similar economic characteristics.

The Company’s reportable segments are as follows:


•	Japan


•	EMEA


•	North America Plasma


•	All Other

The Company has aggregated the Americas Blood Center and Hospital and Asia - Pacific operating segments into the All Other reportable segment based upon their similar operational and economic characteristics, including similarity of operating margin.

Management measures and evaluates the operating segments based on operating income. Management excludes certain corporate expenses from segment operating income. In addition, certain amounts that management considers to be non-recurring or non-operational are excluded from segment operating income because management evaluates the operating results of the segments excluding such items. These items include restructuring and turnaround costs, deal amortization, and asset impairments. Although these amounts are excluded from segment operating income, as applicable, they are included in the reconciliations that follow. Management measures and evaluates the Company's net revenues and operating income using internally derived standard currency exchange rates that remain constant from year to year; therefore, segment information is presented on this basis.

During the first quarter of fiscal 2018, management changed the cost reporting structure such that a portion of corporate expenses were reclassified into the operating segments. Accordingly, the prior year numbers have been updated to reflect this reclassification.

Selected information by business segment is presented below:



	Three Months Ended						Six Months Ended
(In thousands)	September 30, 2017			October 1, 2016			September 30, 2017			October 1, 2016
Net revenues
Japan	$	17,164		$	18,991		$	32,396		$	33,557
EMEA	43,786			45,933			86,794			91,674
North America Plasma	85,051			78,292			162,587			151,767
All Other	80,193			78,411			158,367			156,431
Net revenues before foreign exchange impact	226,194			221,627			440,144			433,429
Effect of exchange rates	(817		)	(1,374		)	(3,816		)	(3,220		)
Net revenues	$	225,377		$	220,253		$	436,328		$	430,209



	Three Months Ended						Six Months Ended
(In thousands)	September 30, 2017			October 1, 2016			September 30, 2017			October 1, 2016
Segment operating income
Japan	$	7,877		$	9,017		$	14,615		$	15,173
EMEA	8,239			8,577			16,810			16,853
North America Plasma	32,184			26,151			56,286			51,318
All Other	30,052			30,946			57,738			58,116
Segment operating income	78,352			74,691			145,449			141,460
Corporate operating expenses	(42,905		)	(41,921		)	(82,216		)	(88,059		)
Effect of exchange rates	1,102			667			(1,099		)	(639		)
Restructuring and turnaround costs	(5,787		)	(1,637		)	(8,270		)	(20,453		)
Deal amortization	(6,504		)	(7,006		)	(12,995		)	(14,081		)
Asset impairments	—			—			—			(1,315		)
Operating income	$	24,258		$	24,794		$	40,869		$	16,913

Our products are organized into four categories for purposes of evaluating their growth potential: Plasma, Blood Center, Cell Processing and Hemostasis Management. Management reviews revenue trends based on these business units; however, no other financial information is currently available on this basis.

Net revenues by business unit are as follows:



	Three Months Ended				Six Months Ended
(In thousands)	September 30, 2017		October 1, 2016		September 30, 2017		October 1, 2016
Plasma	$	109,771	$	103,564	$	211,278	$	201,213
Blood Center	71,710		74,270		137,275		145,213
Cell Processing	25,764		25,955		52,100		52,031
Hemostasis Management	18,132		16,464		35,675		31,752
Net revenues	$	225,377	$	220,253	$	436,328	$	430,209

Net revenues generated in our principle operating regions on a reported basis are as follows:



	Three Months Ended				Six Months Ended
(In thousands)	September 30, 2017		October 1, 2016		September 30, 2017		October 1, 2016
United States	$	138,779	$	130,843	$	269,831	$	256,543
Japan	16,732		21,666		31,648		36,630
Europe	39,133		37,606		76,355		77,973
Asia	28,831		28,384		54,771		55,376
Other	1,902		1,754		3,723		3,687
Net revenues	$	225,377	$	220,253	$	436,328	$	430,209

- Definition

The entire disclosure for reporting segments including data and tables. Reportable segments include those that meet any of the following quantitative thresholds a) it's reported revenue, including sales to external customers and intersegment sales or transfers is 10 percent or more of the combined revenue, internal and external, of all operating segments b) the absolute amount of its reported profit or loss is 10 percent or more of the greater, in absolute amount of 1) the combined reported profit of all operating segments that did not report a loss or 2) the combined reported loss of all operating segments that did report a loss c) its assets are 10 percent or more of the combined assets of all operating segments.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 34
-URI http://asc.fasb.org/extlink&oid=68060357&loc=d3e8981-108599

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 41
-URI http://asc.fasb.org/extlink&oid=68060357&loc=d3e9038-108599

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 33
-URI http://asc.fasb.org/extlink&oid=68060357&loc=d3e8971-108599

Reference 4: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 12
-URI http://asc.fasb.org/extlink&oid=68060357&loc=d3e8595-108599

Reference 5: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=68060357&loc=d3e8380-108599

Reference 6: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 32
-URI http://asc.fasb.org/extlink&oid=68060357&loc=d3e8933-108599

Reference 7: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 26
-URI http://asc.fasb.org/extlink&oid=68060357&loc=d3e8844-108599

Reference 8: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 35
-URI http://asc.fasb.org/extlink&oid=68060357&loc=d3e8984-108599

Reference 9: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 40
-URI http://asc.fasb.org/extlink&oid=68060357&loc=d3e9031-108599

Reference 10: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 42
-URI http://asc.fasb.org/extlink&oid=68060357&loc=d3e9054-108599

Reference 11: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 10
-URI http://asc.fasb.org/extlink&oid=68060357&loc=d3e8538-108599

Reference 12: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 29
-URI http://asc.fasb.org/extlink&oid=68060357&loc=d3e8864-108599

Reference 13: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 31
-URI http://asc.fasb.org/extlink&oid=68060357&loc=d3e8924-108599

Reference 14: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 30
-URI http://asc.fasb.org/extlink&oid=68060357&loc=d3e8906-108599

+ Details

ACCUMULATED OTHER COMPREHENSIVE LOSS

6 Months Ended

Sep. 30, 2017

Stockholders' Equity Note [Abstract]

ACCUMULATED OTHER COMPREHENSIVE LOSS

The components of Accumulated Other Comprehensive Loss are as follows:



(In thousands)	Foreign Currency			Defined Benefit Plans			Net Unrealized Gain/Loss on Derivatives			Total
Balance as of April 1, 2017	$	(29,835	)	$	(2,272	)	$	(766	)	$	(32,873	)
Other comprehensive income (loss) before reclassifications⁽¹⁾	6,856			—			(1,513		)	5,343
Amounts reclassified from Accumulated Other Comprehensive Loss⁽¹⁾	—			—			121			121
Net current period other comprehensive income (loss)	6,856			—			(1,392		)	5,464
Balance as of September 30, 2017	$	(22,979	)	$	(2,272	)	$	(2,158	)	$	(27,409	)

⁽¹⁾ Presented net of income taxes, the amounts of which are insignificant.

- Definition

The entire disclosure for shareholders' equity comprised of portions attributable to the parent entity and noncontrolling interest, including other comprehensive income. Includes, but is not limited to, balances of common stock, preferred stock, additional paid-in capital, other capital and retained earnings, accumulated balance for each classification of other comprehensive income and amount of comprehensive income.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 310
-SubTopic 10
-Section S99
-Paragraph 4
-Subparagraph (SAB Topic 4.E)
-URI http://asc.fasb.org/extlink&oid=27010918&loc=d3e74567-122707

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 4
-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21484-112644

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(29))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 4: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 5
-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21488-112644

Reference 5: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08(e))
-URI http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690

Reference 6: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(31))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 7: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section S99
-Paragraph 4
-Subparagraph (SAB Topic 4.C)
-URI http://asc.fasb.org/extlink&oid=27012166&loc=d3e187143-122770

Reference 8: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(30))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 9: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 6
-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21506-112644

Reference 10: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08(d))
-URI http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690

Reference 11: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.3-04)
-URI http://asc.fasb.org/extlink&oid=27012166&loc=d3e187085-122770

Reference 12: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 30
-Section 50
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=6405834&loc=d3e23285-112656

Reference 13: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21475-112644

Reference 14: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Glossary Preferred Stock
-URI http://asc.fasb.org/extlink&oid=6521494

Reference 15: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21463-112644

Reference 16: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 11
-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21564-112644

+ Details

RESTRUCTURING (Tables)

6 Months Ended

Sep. 30, 2017

Restructuring and Related Activities [Abstract]

Schedule of Restructuring Reserve by Type of Cost

The following summarizes the restructuring activity for the six months ended September 30, 2017:



(In thousands)	Severance and Other Employee Costs			Other Costs			Total Restructuring
Balance at April 1, 2017	$	7,001		$	467		$	7,468
Costs incurred, net of reversals	446			761			1,207
Payments	(3,872		)	(470		)	(4,342		)
Balance at September 30, 2017	$	3,575		$	758		$	4,333

Schedule of Restructuring and Related Costs

The tables below present restructuring and turnaround costs by reportable segment:



Restructuring costs	Three Months Ended					Six Months Ended
(in thousands)	September 30, 2017		October 1, 2016			September 30, 2017		October 1, 2016
Japan	$	2	$	(38	)	$	111	$	836
EMEA	15		(63		)	25		3,011
North America Plasma	—		(7		)	—		368
All Other	134		(246		)	1,071		11,817
Total	$	151	$	(354	)	$	1,207	$	16,032

Turnaround costs	Three Months Ended					Six Months Ended
(in thousands)	September 30, 2017		October 1, 2016			September 30, 2017		October 1, 2016
Japan	$	—	$	1		$	—	$	2
EMEA	20		55			26		81
North America Plasma	197		936			349		936
All Other	5,419		959			6,688		3,362
Total	$	5,636	$	1,951		$	7,063	$	4,381

Total restructuring and turnaround costs	$	5,787	$	1,597		$	8,270	$	20,413

EARNINGS PER SHARE ("EPS") (Tables)

6 Months Ended

Sep. 30, 2017

Earnings Per Share [Abstract]

Schedule of Earnings Per Share Reconciliation

The following table provides a reconciliation of the numerators and denominators of the basic and diluted earnings per share computations.



	Three Months Ended				Six Months Ended
(In thousands, except per share amounts)	September 30, 2017		October 1, 2016		September 30, 2017		October 1, 2016
Basic EPS
Net income	$	20,102	$	19,825	$	40,239	$	9,479
Weighted average shares	52,619		51,378		52,531		51,200
Basic income per share	$	0.38	$	0.39	$	0.77	$	0.19
Diluted EPS
Net income	$	20,102	$	19,825	$	40,239	$	9,479
Basic weighted average shares	52,619		51,378		52,531		51,200
Net effect of common stock equivalents	362		323		365		263
Diluted weighted average shares	52,981		51,701		52,896		51,463
Diluted income per share	$	0.38	$	0.38	$	0.76	$	0.18

INVENTORIES (Tables)

6 Months Ended

Sep. 30, 2017

Inventory Disclosure [Abstract]

Schedule of Inventories

Inventories are stated at the lower of cost or market and include the cost of material, labor and manufacturing overhead. Cost is determined using the first-in, first-out method.



(In thousands)	September 30, 2017		April 1, 2017
Raw materials	$	50,197	$	52,052
Work-in-process	12,234		10,400
Finished goods	106,161		114,477
Total inventories	$	168,592	$	176,929

PRODUCT WARRANTIES (Tables)

6 Months Ended

Sep. 30, 2017

Product Warranties Disclosures [Abstract]

Schedule of Product Warranty Liability

We estimate our potential warranty expense based on our historical warranty experience and periodically assess the adequacy of our warranty accrual, making adjustments as necessary.



	Six Months Ended
(In thousands)	September 30, 2017			October 1, 2016
Warranty accrual as of the beginning of the period	$	176		$	420
Warranty provision	796			390
Warranty spending	(537		)	(583		)
Warranty accrual as of the end of the period	$	435		$	227

DERIVATIVES AND FAIR VALUE MEASUREMENTS (Tables)

6 Months Ended

Sep. 30, 2017

Derivative Instruments and Hedging Activities Disclosure [Abstract]

Schedule of Effect of Derivative Instruments Designated as Cash Flow Hedges and Those Not Designated as Hedging Instruments



(In thousands)	Amount of (Loss) Gain Recognized in Accumulated Other Comprehensive Loss			Amount of (Loss) Gain Reclassified from Accumulated Other Comprehensive Loss into Earnings			Location in Consolidated Statements of Income and Comprehensive Income	Amount of Gain (Loss) Excluded from Effectiveness Testing			Location in Consolidated Statements of Income and Comprehensive Income
Designated foreign currency hedge contracts, net of tax	$	(1,449	)	$	(121	)	Net revenues, COGS, and SG&A	$	601		Interest and other expense, net
Non-designated foreign currency hedge contracts	—			—				$	(881	)	Interest and other expense, net
Designated interest rate swaps, net of tax	$	(64	)				Interest and other expense, net

Schedule of Fair Value of Derivative Instruments as They Appear in Consolidated Balance Sheets

The following tables present the fair value of our derivative instruments as they appear in our consolidated balance sheets as of September 30, 2017 and April 1, 2017:



(In thousands)	Location in Balance Sheet	As of September 30, 2017		As of April 1, 2017
Derivative Assets:
Designated foreign currency hedge contracts	Other current assets	$	1,093	$	1,645
Non-designated foreign currency hedge contracts	Other current assets	64		218
Designated interest rate swaps	Other current assets	—		64
		$	1,157	$	1,927
Derivative Liabilities:
Designated foreign currency hedge contracts	Other current liabilities	$	1,611	$	894
Non-designated foreign currency hedge contracts	Other current liabilities	141		72
		$	1,752	$	966

Schedule of Financial Assets and Financial Liabilities Measured at Fair Value on a Recurring Basis

Financial assets and financial liabilities measured at fair value on a recurring basis consist of the following as of September 30, 2017 and April 1, 2017.



	As of September 30, 2017
(In thousands)	Level 1		Level 2		Total
Assets
Money market funds	$	135,763	$	—	$	135,763
Designated foreign currency hedge contracts	—		1,093		1,093
Non-designated foreign currency hedge contracts	—		64		64
	$	135,763	$	1,157	$	136,920
Liabilities
Designated foreign currency hedge contracts	$	—	$	1,611	$	1,611
Non-designated foreign currency hedge contracts	—		141		141
	$	—	$	1,752	$	1,752

	As of April 1, 2017
	Level 1		Level 2		Total
Assets
Money market funds	$	80,676	$	—	$	80,676
Designated foreign currency hedge contracts	—		1,645		1,645
Non-designated foreign currency hedge contracts	—		218		218
Designated interest rate swaps	—		64		64
	$	80,676	$	1,927	$	82,603
Liabilities
Designated foreign currency hedge contracts	$	—	$	894	$	894
Non-designated foreign currency hedge contracts	—		72		72
	$	—	$	966	$	966

SEGMENT AND ENTERPRISE-WIDE INFORMATION (Tables)

6 Months Ended

Sep. 30, 2017

Segment Reporting [Abstract]

Selected Information by Business Segment

Selected information by business segment is presented below:



	Three Months Ended						Six Months Ended
(In thousands)	September 30, 2017			October 1, 2016			September 30, 2017			October 1, 2016
Net revenues
Japan	$	17,164		$	18,991		$	32,396		$	33,557
EMEA	43,786			45,933			86,794			91,674
North America Plasma	85,051			78,292			162,587			151,767
All Other	80,193			78,411			158,367			156,431
Net revenues before foreign exchange impact	226,194			221,627			440,144			433,429
Effect of exchange rates	(817		)	(1,374		)	(3,816		)	(3,220		)
Net revenues	$	225,377		$	220,253		$	436,328		$	430,209



	Three Months Ended						Six Months Ended
(In thousands)	September 30, 2017			October 1, 2016			September 30, 2017			October 1, 2016
Segment operating income
Japan	$	7,877		$	9,017		$	14,615		$	15,173
EMEA	8,239			8,577			16,810			16,853
North America Plasma	32,184			26,151			56,286			51,318
All Other	30,052			30,946			57,738			58,116
Segment operating income	78,352			74,691			145,449			141,460
Corporate operating expenses	(42,905		)	(41,921		)	(82,216		)	(88,059		)
Effect of exchange rates	1,102			667			(1,099		)	(639		)
Restructuring and turnaround costs	(5,787		)	(1,637		)	(8,270		)	(20,453		)
Deal amortization	(6,504		)	(7,006		)	(12,995		)	(14,081		)
Asset impairments	—			—			—			(1,315		)
Operating income	$	24,258		$	24,794		$	40,869		$	16,913

Schedule of Revenues by Product Line and Geographic Regions

Net revenues by business unit are as follows:



	Three Months Ended				Six Months Ended
(In thousands)	September 30, 2017		October 1, 2016		September 30, 2017		October 1, 2016
Plasma	$	109,771	$	103,564	$	211,278	$	201,213
Blood Center	71,710		74,270		137,275		145,213
Cell Processing	25,764		25,955		52,100		52,031
Hemostasis Management	18,132		16,464		35,675		31,752
Net revenues	$	225,377	$	220,253	$	436,328	$	430,209

Net revenues generated in our principle operating regions on a reported basis are as follows:



	Three Months Ended				Six Months Ended
(In thousands)	September 30, 2017		October 1, 2016		September 30, 2017		October 1, 2016
United States	$	138,779	$	130,843	$	269,831	$	256,543
Japan	16,732		21,666		31,648		36,630
Europe	39,133		37,606		76,355		77,973
Asia	28,831		28,384		54,771		55,376
Other	1,902		1,754		3,723		3,687
Net revenues	$	225,377	$	220,253	$	436,328	$	430,209

ACCUMULATED OTHER COMPREHENSIVE LOSS (Tables)

6 Months Ended

Sep. 30, 2017

Stockholders' Equity Note [Abstract]

Schedule of Accumulated Other Comprehensive Income (Loss)

The components of Accumulated Other Comprehensive Loss are as follows:



(In thousands)	Foreign Currency			Defined Benefit Plans			Net Unrealized Gain/Loss on Derivatives			Total
Balance as of April 1, 2017	$	(29,835	)	$	(2,272	)	$	(766	)	$	(32,873	)
Other comprehensive income (loss) before reclassifications⁽¹⁾	6,856			—			(1,513		)	5,343
Amounts reclassified from Accumulated Other Comprehensive Loss⁽¹⁾	—			—			121			121
Net current period other comprehensive income (loss)	6,856			—			(1,392		)	5,464
Balance as of September 30, 2017	$	(22,979	)	$	(2,272	)	$	(2,158	)	$	(27,409	)

⁽¹⁾ Presented net of income taxes, the amounts of which are insignificant.

BASIS OF PRESENTATION (Details) - USD ($) $ in Millions	3 Months Ended	6 Months Ended
BASIS OF PRESENTATION (Details) - USD ($) $ in Millions	Oct. 01, 2016	Oct. 01, 2016
Overstatement of Net Income [Member]
Quantifying Misstatement in Current Year Financial Statements [Line Items]
Amount of correction	$ (0.9)	$ (1.2)

RECENT ACCOUNTING PRONOUNCEMENTS (Narrative) (Details) - USD ($) $ in Millions	6 Months Ended	12 Months Ended
	Oct. 01, 2016	Apr. 01, 2017
New Accounting Pronouncements or Change in Accounting Principle [Line Items]
Cumulative-effect adjustment to accumulated deficit and deferred tax assets for certain off balance sheet federal and state net operating loss carry-forwards	$ 1.4
Accounting Standards Update 2016-09 [Member]
New Accounting Pronouncements or Change in Accounting Principle [Line Items]
Cumulative-effect adjustment to accumulated deficit and deferred tax assets for certain off balance sheet federal and state net operating loss carry-forwards		$ 1.6

RESTRUCTURING (Narrative) (Details) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Sep. 30, 2017	Oct. 01, 2016	Sep. 30, 2017	Oct. 01, 2016	Nov. 01, 2017	Apr. 01, 2017
Restructuring Cost and Reserve [Line Items]
Restructuring and turnaround costs	$ 5,787	$ 1,597	$ 8,270	$ 20,413
Restructuring liability	4,333		4,333			$ 7,468
Restructuring liability payable in next twelve months	3,900		3,900
Restructuring costs	151	(354)	1,207	16,032
Turnaround costs	5,636	1,951	7,063	4,381
Severance and Other Employee Costs
Restructuring Cost and Reserve [Line Items]
Restructuring liability	3,575		3,575			$ 7,001
Restructuring costs			446
2017 Program [Member]
Restructuring Cost and Reserve [Line Items]
Restructuring and turnaround costs	$ 5,200	$ 1,100	$ 7,700	$ 18,800
Subsequent Event [Member] \| 2018 Program [Member] \| Minimum
Restructuring Cost and Reserve [Line Items]
Expected cost					$ 50,000
Subsequent Event [Member] \| 2018 Program [Member] \| Minimum \| Severance and Other Employee Costs
Restructuring Cost and Reserve [Line Items]
Expected cost					35,000
Subsequent Event [Member] \| 2018 Program [Member] \| Maximum
Restructuring Cost and Reserve [Line Items]
Expected cost					60,000
Subsequent Event [Member] \| 2018 Program [Member] \| Maximum \| Severance and Other Employee Costs
Restructuring Cost and Reserve [Line Items]
Expected cost					$ 40,000

RESTRUCTURING (Schedule of Restructuring Reserve by Type of Cost) (Details) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Sep. 30, 2017	Oct. 01, 2016	Sep. 30, 2017	Oct. 01, 2016
Restructuring Reserve [Roll Forward]
Balance at April 1, 2017			$ 7,468
Costs incurred, net of reversals	$ 151	$ (354)	1,207	$ 16,032
Payments			(4,342)
Balance at September 30, 2017	4,333		4,333
Severance and Other Employee Costs
Restructuring Reserve [Roll Forward]
Balance at April 1, 2017			7,001
Costs incurred, net of reversals			446
Payments			(3,872)
Balance at September 30, 2017	3,575		3,575
Other Costs
Restructuring Reserve [Roll Forward]
Balance at April 1, 2017			467
Costs incurred, net of reversals			761
Payments			(470)
Balance at September 30, 2017	$ 758		$ 758

RESTRUCTURING (Schedule of Restructuring and Related Costs) (Details) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Sep. 30, 2017	Oct. 01, 2016	Sep. 30, 2017	Oct. 01, 2016
Restructuring Cost and Reserve [Line Items]
Restructuring costs	$ 151	$ (354)	$ 1,207	$ 16,032
Turnaround costs	5,636	1,951	7,063	4,381
Total restructuring and turnaround costs	5,787	1,597	8,270	20,413
Severance and Other Employee Costs
Restructuring Cost and Reserve [Line Items]
Restructuring costs			446
Other Costs
Restructuring Cost and Reserve [Line Items]
Restructuring costs			761
Japan
Restructuring Cost and Reserve [Line Items]
Restructuring costs	2	(38)	111	836
Turnaround costs	0	1	0	2
EMEA
Restructuring Cost and Reserve [Line Items]
Restructuring costs	15	(63)	25	3,011
Turnaround costs	20	55	26	81
North America Plasma
Restructuring Cost and Reserve [Line Items]
Restructuring costs	0	(7)	0	368
Turnaround costs	197	936	349	936
All Other
Restructuring Cost and Reserve [Line Items]
Restructuring costs	134	(246)	1,071	11,817
Turnaround costs	$ 5,419	$ 959	$ 6,688	$ 3,362

DIVESTITURE (Details) - USD ($) $ in Thousands		3 Months Ended		6 Months Ended
DIVESTITURE (Details) - USD ($) $ in Thousands	Apr. 27, 2017	Sep. 30, 2017	Oct. 01, 2016	Sep. 30, 2017	Oct. 01, 2016
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Proceeds from divestiture				$ 9,000	$ 0
Gain on divestiture		$ 0	$ 0	$ 8,000	$ 0
SEBRA Sealers Product Line [Member] \| Disposal Group, Disposed of by Sale, Not Discontinued Operations [Member]
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Proceeds from divestiture	$ 9,000
Gain on divestiture	$ 8,000

INCOME TAXES (Details) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
INCOME TAXES (Details) - USD ($) $ in Thousands	Sep. 30, 2017	Oct. 01, 2016	Sep. 30, 2017	Oct. 01, 2016
Income Tax Disclosure [Abstract]
Provision (benefit) for income taxes	$ 2,759	$ 3,007	$ 5,874	$ 3,295
Reported tax rate	12.10%	13.20%	12.70%	25.80%
Discrete tax provision				$ 1,400

EARNINGS PER SHARE ("EPS") (Schedule of Earnings Per Share Reconciliation) (Details) - USD ($) $ / shares in Units, shares in Thousands, $ in Thousands	3 Months Ended		6 Months Ended
	Sep. 30, 2017	Oct. 01, 2016	Sep. 30, 2017	Oct. 01, 2016
Basic EPS
Net income	$ 20,102	$ 19,825	$ 40,239	$ 9,479
Basic weighted average shares (in shares)	52,619	51,378	52,531	51,200
Basic income per share (in dollars per share)	$ 0.38	$ 0.39	$ 0.77	$ 0.19
Diluted EPS
Net income	$ 20,102	$ 19,825	$ 40,239	$ 9,479
Basic weighted average shares (in shares)	52,619	51,378	52,531	51,200
Net effect of common stock equivalents (in shares)	362	323	365	263
Diluted weighted average shares (in shares)	52,981	51,701	52,896	51,463
Diluted income per share (in dollars per share)	$ 0.38	$ 0.38	$ 0.76	$ 0.18
Anti-dilutive shares excluded (in shares)	900	1,700	800	1,700

INVENTORIES (Schedule of Inventories) (Details) - USD ($) $ in Thousands	Sep. 30, 2017	Apr. 01, 2017
Inventory Disclosure [Abstract]
Raw materials	$ 50,197	$ 52,052
Work-in-process	12,234	10,400
Finished goods	106,161	114,477
Inventories, net	$ 168,592	$ 176,929

CAPITALIZATION OF SOFTWARE DEVELOPMENT COSTS (Narrative) (Details) - USD ($)	3 Months Ended	6 Months Ended
	Sep. 30, 2017	Sep. 30, 2017	Oct. 01, 2016	Apr. 01, 2017
Research and Development [Abstract]
Capitalized software development costs for ongoing initiatives	$ 6,400,000	$ 6,400,000
Software costs capitalized, net	69,100,000	69,100,000		$ 62,700,000
Total costs capitalized related to in process software development initiatives	$ 19,100,000	19,100,000		$ 12,700,000
Capitalized software development costs placed into service		$ 0	$ 4,500,000

PRODUCT WARRANTIES (Schedule of Product Warranty Liability) (Details) - USD ($) $ in Thousands	6 Months Ended
	Sep. 30, 2017	Oct. 01, 2016
Product Warranties Disclosures [Abstract]
General Warranty Period on Parts and Labor	1 year
Product Warranties [Roll Forward]
Warranty accrual as of the beginning of the period	$ 176	$ 420
Warranty provision	796	390
Warranty spending	(537)	(583)
Warranty accrual as of the end of the period	$ 435	$ 227

DERIVATIVES AND FAIR VALUE MEASUREMENTS (Schedule of Effect of Derivative Instruments Designated as Cash Flow Hedges and Those Not Designated as Hedging Instruments) (Details) $ in Thousands	6 Months Ended
	Sep. 30, 2017 USD ($)
Designated as Hedging Instrument \| Cash Flow Hedging \| Net revenues, COGS, and SG&A
Derivative Instruments, Gain (Loss) [Line Items]
Amount of Gain (Loss) Recognized in AOCI (Effective Portion)	$ (1,449)
Amount of Gain/(Loss) Reclassified from AOCI into Earnings (Effective Portion)	(121)
Designated as Hedging Instrument \| Cash Flow Hedging \| Interest and other expense, net
Derivative Instruments, Gain (Loss) [Line Items]
Amount Excluded from Effectiveness Testing	601
Designated as Hedging Instrument \| Interest Rate Swap [Member]
Derivative Instruments, Gain (Loss) [Line Items]
Amount Excluded from Effectiveness Testing
Designated as Hedging Instrument \| Interest Rate Swap [Member] \| Interest and other expense, net
Derivative Instruments, Gain (Loss) [Line Items]
Amount of Gain (Loss) Recognized in AOCI (Effective Portion)	(64)
Amount of Gain/(Loss) Reclassified from AOCI into Earnings (Effective Portion)
Not Designated as Hedging Instrument \| Foreign Exchange Contract
Derivative Instruments, Gain (Loss) [Line Items]
Amount of Gain (Loss) Recognized in AOCI (Effective Portion)	0
Amount of Gain/(Loss) Reclassified from AOCI into Earnings (Effective Portion)	0
Not Designated as Hedging Instrument \| Foreign Exchange Contract \| Interest and other expense, net
Derivative Instruments, Gain (Loss) [Line Items]
Amount Excluded from Effectiveness Testing	$ (881)

DERIVATIVES AND FAIR VALUE MEASUREMENTS (Schedule of Fair Value of Derivative Instruments as They Appear in Consolidated Balance Sheets) (Details) - USD ($) $ in Thousands	Sep. 30, 2017	Apr. 01, 2017
Designated as Hedging Instrument
Derivative Assets:
Derivative Assets	$ 1,157	$ 1,927
Derivative Liabilities:
Derivative Liabilities	1,752	966
Designated as Hedging Instrument \| Foreign Exchange Contract \| Other Current Assets
Derivative Assets:
Derivative Assets		1,645
Designated as Hedging Instrument \| Foreign Exchange Contract \| Other Current Liabilities
Derivative Liabilities:
Derivative Liabilities		894
Designated as Hedging Instrument \| Interest Rate Swap [Member] \| Other Current Assets
Derivative Assets:
Derivative Assets	$ 0	64
Not Designated as Hedging Instrument \| Foreign Exchange Contract \| Other Current Assets
Derivative Assets:
Derivative Assets		218
Not Designated as Hedging Instrument \| Foreign Exchange Contract \| Other Current Liabilities
Derivative Liabilities:
Derivative Liabilities		$ 72

DERIVATIVES AND FAIR VALUE MEASUREMENTS (Schedule of Financial Assets and Financial Liabilities Measured at Fair Value) (Details) - USD ($) $ in Thousands	Sep. 30, 2017	Apr. 01, 2017
Fair Value, Measurements, Recurring [Member]
Assets
Money market funds	$ 135,763	$ 80,676
Designated interest rate swaps		64
Assets fair value	136,920	82,603
Liabilities
Liabilities fair value	1,752	966
Fair Value, Measurements, Recurring [Member] \| Quoted Market Prices for Identical Assets (Level 1)
Assets
Money market funds	135,763	80,676
Designated interest rate swaps		0
Assets fair value	135,763	80,676
Liabilities
Liabilities fair value	0	0
Fair Value, Measurements, Recurring [Member] \| Significant Other Observable Inputs (Level 2)
Assets
Money market funds	0	0
Designated interest rate swaps		64
Assets fair value	1,157	1,927
Liabilities
Liabilities fair value	1,752	966
Designated as Hedging Instrument
Assets
Derivative Assets	1,157	1,927
Liabilities
Derivative Liabilities	1,752	966
Designated as Hedging Instrument \| Fair Value, Measurements, Recurring [Member]
Assets
Designated foreign currency hedge contracts	1,093	1,645
Liabilities
Designated foreign currency hedge contracts	1,611	894
Designated as Hedging Instrument \| Fair Value, Measurements, Recurring [Member] \| Quoted Market Prices for Identical Assets (Level 1)
Assets
Designated foreign currency hedge contracts	0	0
Liabilities
Designated foreign currency hedge contracts	0	0
Designated as Hedging Instrument \| Fair Value, Measurements, Recurring [Member] \| Significant Other Observable Inputs (Level 2)
Assets
Designated foreign currency hedge contracts		1,645
Liabilities
Designated foreign currency hedge contracts		894
Not Designated as Hedging Instrument \| Fair Value, Measurements, Recurring [Member]
Assets
Designated foreign currency hedge contracts	64	218
Liabilities
Designated foreign currency hedge contracts	141	72
Not Designated as Hedging Instrument \| Fair Value, Measurements, Recurring [Member] \| Quoted Market Prices for Identical Assets (Level 1)
Assets
Designated foreign currency hedge contracts	0	0
Liabilities
Designated foreign currency hedge contracts	0	0
Not Designated as Hedging Instrument \| Fair Value, Measurements, Recurring [Member] \| Significant Other Observable Inputs (Level 2)
Assets
Designated foreign currency hedge contracts		218
Liabilities
Designated foreign currency hedge contracts		72
Foreign Exchange Contract \| Other Current Assets \| Designated as Hedging Instrument
Assets
Derivative Assets		1,645
Foreign Exchange Contract \| Other Current Assets \| Designated as Hedging Instrument \| Fair Value, Measurements, Recurring [Member] \| Significant Other Observable Inputs (Level 2)
Assets
Derivative Assets	1,093
Foreign Exchange Contract \| Other Current Assets \| Not Designated as Hedging Instrument
Assets
Derivative Assets		218
Foreign Exchange Contract \| Other Current Assets \| Not Designated as Hedging Instrument \| Fair Value, Measurements, Recurring [Member] \| Significant Other Observable Inputs (Level 2)
Assets
Derivative Assets	64
Foreign Exchange Contract \| Other Current Liabilities \| Designated as Hedging Instrument
Liabilities
Derivative Liabilities		894
Foreign Exchange Contract \| Other Current Liabilities \| Designated as Hedging Instrument \| Fair Value, Measurements, Recurring [Member] \| Significant Other Observable Inputs (Level 2)
Liabilities
Derivative Liabilities	1,611
Foreign Exchange Contract \| Other Current Liabilities \| Not Designated as Hedging Instrument
Liabilities
Derivative Liabilities		$ 72
Foreign Exchange Contract \| Other Current Liabilities \| Not Designated as Hedging Instrument \| Fair Value, Measurements, Recurring [Member] \| Significant Other Observable Inputs (Level 2)
Liabilities
Derivative Liabilities	$ 141

DERIVATIVES AND FAIR VALUE MEASUREMENTS (Narrative) (Details)	3 Months Ended	6 Months Ended
	Sep. 30, 2017 USD ($)	Sep. 30, 2017 USD ($)	Apr. 01, 2017 USD ($)	Dec. 21, 2012 USD ($) swap
Foreign Exchange Contract
Derivative [Line Items]
Percentage of sales generated outside the US	38.40%	38.20%
Maturity period for foreign currency contracts		1 year
Designated as Hedging Instrument \| Foreign Exchange Contract
Derivative [Line Items]
Deferred income tax expense (benefit)	$ 0	$ 0
Designated as Hedging Instrument \| Foreign Exchange Contract
Derivative [Line Items]
Designated foreign currency hedge contracts outstanding	58,400,000	58,400,000	$ 68,400,000
Designated as Hedging Instrument \| Cash Flow Hedging
Derivative [Line Items]
Gain (loss) to be reclassified within the next twelve months		(1,400,000)
Designated as Hedging Instrument \| Interest Rate Swap [Member]
Derivative [Line Items]
Number of interest rate derivatives held \| swap				2
Notional amount of derivative				$ 250,000,000
Not Designated as Hedging Instrument \| Foreign Exchange Contract
Derivative [Line Items]
Amount of Gain/(Loss) Reclassified from AOCI into Earnings (Effective Portion)		0
Non-designated foreign currency hedge contracts outstanding	$ 37,600,000	37,600,000	$ 55,400,000
Net revenues, COGS, and SG&A \| Designated as Hedging Instrument \| Cash Flow Hedging
Derivative [Line Items]
Amount of Gain/(Loss) Reclassified from AOCI into Earnings (Effective Portion)		$ (121,000)

COMMITMENTS AND CONTINGENCIES (Details) - USD ($)	1 Months Ended			6 Months Ended	12 Months Ended
COMMITMENTS AND CONTINGENCIES (Details) - USD ($)	Feb. 28, 2017	Jul. 31, 2016	Apr. 30, 2013	Sep. 30, 2017	Apr. 01, 2017
Product Recall
Loss Contingencies [Line Items]
Damages claimed					$ 14,200,000
Loss in period					7,100,000
Product Recall \| Minimum
Loss Contingencies [Line Items]
Estimate of possible loss					3,400,000
Product Recall \| Maximum
Loss Contingencies [Line Items]
Estimate of possible loss					14,200,000
Product Recall \| Customer Returns and Inventory Reserves [Member]
Loss Contingencies [Line Items]
Loss in period					3,700,000
Product Recall \| Customer Claims [Member]
Loss Contingencies [Line Items]
Loss in period					$ 3,400,000
Insurance settlements receivable				$ 2,900,000
Contract Termination [Member]
Loss Contingencies [Line Items]
Damages claimed	$ 4,600,000
Estimate of possible loss				2,800,000
Performance Guarantee [Member]
Loss Contingencies [Line Items]
Damages claimed	2,800,000
Up-front Payment Arrangement [Member]
Loss Contingencies [Line Items]
Damages claimed	$ 1,800,000
Italian Employment Litigation [Member]
Loss Contingencies [Line Items]
Damages claimed				4,800,000
Estimate of possible loss				800,000
Loss in period				400,000
Amount accrued				800,000
SOLX Arbitration [Member]
Loss Contingencies [Line Items]
Damages claimed		$ 17,000,000
Amount accrued				$ 400,000.0
Payments under previous acquisition			$ 24,000,000
Contingent milestone payment			3,000,000
Maximum future royalty payments			$ 14,000,000
Royalty Term			10 years

SEGMENT AND ENTERPRISE-WIDE INFORMATION (Details) $ in Thousands	3 Months Ended		6 Months Ended
	Sep. 30, 2017 USD ($)	Oct. 01, 2016 USD ($)	Sep. 30, 2017 USD ($) unit	Oct. 01, 2016 USD ($)
Segment Reporting [Abstract]
Number of business units \| unit			4
Segment Reporting Information [Line Items]
Net Revenues, Before Foreign Exchange Impact	$ 226,194	$ 221,627	$ 440,144	$ 433,429
Effect of exchange rates	(817)	(1,374)	(3,816)	(3,220)
Net revenues (reported)	225,377	220,253	436,328	430,209
Effect of exchange rates	1,102	667	(1,099)	(639)
Restructuring and turnaround costs	(5,787)	(1,637)	(8,270)	(20,453)
Deal amortization	(6,504)	(7,006)	(12,995)	(14,081)
Impairment of assets	0	0	0	(1,315)
Operating income	24,258	24,794	40,869	16,913
Plasma [Member]
Segment Reporting Information [Line Items]
Net revenues (reported)	109,771	103,564	211,278	201,213
Blood Center [Member]
Segment Reporting Information [Line Items]
Net revenues (reported)	71,710	74,270	137,275	145,213
Cell Processing Management [Member]
Segment Reporting Information [Line Items]
Net revenues (reported)	25,764	25,955	52,100	52,031
Hemostasis Management [Member]
Segment Reporting Information [Line Items]
Net revenues (reported)	18,132	16,464	35,675	31,752
United States
Segment Reporting Information [Line Items]
Net revenues (reported)	138,779	130,843	269,831	256,543
Japan
Segment Reporting Information [Line Items]
Net revenues (reported)	16,732	21,666	31,648	36,630
Europe
Segment Reporting Information [Line Items]
Net revenues (reported)	39,133	37,606	76,355	77,973
Asia
Segment Reporting Information [Line Items]
Net revenues (reported)	28,831	28,384	54,771	55,376
Other
Segment Reporting Information [Line Items]
Net revenues (reported)	1,902	1,754	3,723	3,687
Japan
Segment Reporting Information [Line Items]
Net Revenues, Before Foreign Exchange Impact	17,164	18,991	32,396	33,557
EMEA
Segment Reporting Information [Line Items]
Net Revenues, Before Foreign Exchange Impact	43,786	45,933	86,794	91,674
North America Plasma
Segment Reporting Information [Line Items]
Net Revenues, Before Foreign Exchange Impact	85,051	78,292	162,587	151,767
All Other
Segment Reporting Information [Line Items]
Net Revenues, Before Foreign Exchange Impact	80,193	78,411	158,367	156,431
Operating Segments
Segment Reporting Information [Line Items]
Operating income	78,352	74,691	145,449	141,460
Operating Segments \| Japan
Segment Reporting Information [Line Items]
Operating income	7,877	9,017	14,615	15,173
Operating Segments \| EMEA
Segment Reporting Information [Line Items]
Operating income	8,239	8,577	16,810	16,853
Operating Segments \| North America Plasma
Segment Reporting Information [Line Items]
Operating income	32,184	26,151	56,286	51,318
Operating Segments \| All Other
Segment Reporting Information [Line Items]
Operating income	30,052	30,946	57,738	58,116
Corporate operating expenses
Segment Reporting Information [Line Items]
Corporate operating expenses	$ (42,905)	$ (41,921)
Operating income			$ 82,216	$ 88,059

ACCUMULATED OTHER COMPREHENSIVE LOSS (Details 1) $ in Thousands	6 Months Ended
	Sep. 30, 2017 USD ($)
Accumulated Other Comprehensive Income (Loss), Net of Tax [Roll Forward]
Balance as of April 1, 2017	$ (32,873)
Other comprehensive income (loss) before reclassifications	5,343
Amounts reclassified from Accumulated Other Comprehensive Income (Loss)	121
Other comprehensive income (loss)	5,464
Balance as of September 30, 2017	(27,409)
Foreign Currency
Accumulated Other Comprehensive Income (Loss), Net of Tax [Roll Forward]
Balance as of April 1, 2017	(29,835)
Other comprehensive income (loss) before reclassifications	6,856
Amounts reclassified from Accumulated Other Comprehensive Income (Loss)	0
Other comprehensive income (loss)	6,856
Balance as of September 30, 2017	(22,979)
Defined Benefit Plans
Accumulated Other Comprehensive Income (Loss), Net of Tax [Roll Forward]
Balance as of April 1, 2017	(2,272)
Other comprehensive income (loss) before reclassifications	0
Amounts reclassified from Accumulated Other Comprehensive Income (Loss)	0
Other comprehensive income (loss)	0
Balance as of September 30, 2017	(2,272)
Net Unrealized Gain/Loss on Derivatives
Accumulated Other Comprehensive Income (Loss), Net of Tax [Roll Forward]
Balance as of April 1, 2017	(766)
Other comprehensive income (loss) before reclassifications	(1,513)
Amounts reclassified from Accumulated Other Comprehensive Income (Loss)	121
Other comprehensive income (loss)	(1,392)
Balance as of September 30, 2017	$ (2,158)